Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
MOLN
Upturn stock ratingUpturn stock rating

Molecular Partners AG ADR (MOLN)

Upturn stock ratingUpturn stock rating
$3.76
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/27/2025: MOLN (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

4 Analysts rated it

These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.

Year Target Price $10.87

Year Target Price $10.87

Analyst’s Price TargetsFor last 52 week
$10.87Target price
Low$3.36
Current$3.76
high$12.22

Analysis of Past Performance

Type Stock
Historic Profit 28.94%
Avg. Invested days 32
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 3.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/27/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 138.65M USD
Price to earnings Ratio -
1Y Target Price 10.96
Price to earnings Ratio -
1Y Target Price 10.96
Volume (30-day avg) -
Beta 0.52
52 Weeks Range 3.36 - 12.22
Updated Date 06/29/2025
52 Weeks Range 3.36 - 12.22
Updated Date 06/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -2.11

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -1231.73%

Management Effectiveness

Return on Assets (TTM) -21.44%
Return on Equity (TTM) -33.98%

Valuation

Trailing PE -
Forward PE 1.78
Enterprise Value -24488850
Price to Sales(TTM) 27.9
Enterprise Value -24488850
Price to Sales(TTM) 27.9
Enterprise Value to Revenue 3.81
Enterprise Value to EBITDA 1.23
Shares Outstanding 36874600
Shares Floating 14882000
Shares Outstanding 36874600
Shares Floating 14882000
Percent Insiders -
Percent Institutions 9.72

Analyst Ratings

Rating 4.5
Target Price 10.87
Buy -
Strong Buy 3
Buy -
Strong Buy 3
Hold 1
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Molecular Partners AG ADR

stock logo

Company Overview

overview logo History and Background

Molecular Partners AG was founded in 2004 and is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of a class of targeted protein therapeutics known as DARPins. Its initial focus was on ophthalmology and oncology but has expanded since.

business area logo Core Business Areas

  • DARPin Therapeutics Development: The core business revolves around developing DARPin therapeutics, a novel class of targeted protein therapeutics designed to address limitations of conventional antibody therapies.
  • Research and Development: Focuses on the discovery and preclinical development of new DARPin candidates across different therapeutic areas.
  • Partnerships and Licensing: Strategic collaborations with pharmaceutical companies to co-develop or license DARPin candidates.

leadership logo Leadership and Structure

The leadership team consists of experienced executives in biotechnology and pharmaceutical development. The organizational structure comprises research, development, clinical, and commercial teams.

Top Products and Market Share

overview logo Key Offerings

  • Ensovibep: A DARPin therapeutic developed in collaboration with Novartis for the treatment of COVID-19. Market share is difficult to pinpoint since it is related to COVID-19 vaccines and other treatments which will fluctuate over time. Competitors in this segment include Pfizer (PAXLOVID), Merck (Molnupiravir), and various vaccine manufacturers (MRNA, PFE, NVAX).
  • MP0310 (AMG 506): An anti-FAP DARPin immuno-oncology agent being co-developed with Amgen. Specific market share data is currently unavailable, as it is still in development. Competitors are other immuno-oncology drugs such as Keytruda (MRK) and Opdivo (BMY).

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is characterized by high research and development costs, stringent regulatory requirements, and intense competition. Advancements in protein engineering and targeted therapies are driving innovation.

Positioning

Molecular Partners AG is positioned as a leader in DARPin therapeutics, offering potential advantages over traditional antibodies in terms of size, stability, and multi-specificity. Their competitive advantage lies in their DARPin technology platform.

Total Addressable Market (TAM)

The TAM for targeted protein therapeutics is substantial, estimated to be in the billions of dollars, encompassing areas like oncology, ophthalmology, and infectious diseases. Molecular Partners AG is positioning itself to capture a share of this market through its DARPin platform and partnerships.

Upturn SWOT Analysis

Strengths

  • Novel DARPin technology platform
  • Strategic partnerships with established pharmaceutical companies
  • Experienced leadership team
  • Potential for rapid drug development

Weaknesses

  • Reliance on partnerships for funding and development
  • Limited commercial infrastructure
  • Clinical trial risks and regulatory hurdles
  • Relatively small company size

Opportunities

  • Expansion into new therapeutic areas
  • Advancement of DARPin candidates through clinical trials
  • Increased adoption of targeted protein therapeutics
  • Further strategic partnerships

Threats

  • Competition from established pharmaceutical companies
  • Clinical trial failures
  • Regulatory setbacks
  • Patent disputes

Competitors and Market Share

competitor logo Key Competitors

  • MRK
  • BMY
  • LLY
  • PFE

Competitive Landscape

Molecular Partners AG faces competition from established pharmaceutical companies with greater resources and broader product portfolios. Its competitive advantage lies in its novel DARPin technology, but it needs to navigate regulatory hurdles and secure further partnerships to compete effectively.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been dependent on research milestones, clinical trial progress, and partnership deals.

Future Projections: Future growth is tied to the successful development and commercialization of DARPin therapeutics, expansion of strategic partnerships, and market acceptance of the DARPin technology platform. Analyst estimates can vary widely.

Recent Initiatives: Recent initiatives include advancing clinical trials for lead candidates, expanding research collaborations, and exploring new therapeutic applications for DARPins.

Summary

Molecular Partners AG is a clinical-stage biopharmaceutical company with a novel DARPin technology platform. Its success hinges on the progression of its clinical trials and continued collaboration with larger pharmaceutical companies. The company faces risks associated with drug development and competition, but its innovative technology provides a strong foundation for potential growth. Financial information is not available in real-time, so please refer to official company reports.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Industry Reports
  • Financial News Sources

Disclaimers:

The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share estimates are approximations and subject to change.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Molecular Partners AG ADR

Exchange NASDAQ
Headquaters -
IPO Launch date 2021-06-16
Co-Founder, CEO, Member of Management Board & Director Dr. Patrick Amstutz Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 158
Full time employees 158

Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in preclinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and Radio-DARPin Therapy to treat ovarian disease. In addition, the company develops MP0621, a molecular partners' first Switch-DARPin program, which is in preclinical trial designed to induce killing of hematopoietic stem cells (HSCs) as a next-generation conditioning regimen for HSC transplantation (HSCT); and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.